Kornimate/medical-research-clean huggingface dataset:
investigation of the effectiveness of short wave diathermy treatment in patients with hand osteoarthritis

Conditions: Hand Osteoarthritis; Osteoarthritis

Summary: the aim of this randomized, double-blind, placebo-controlled study was to evaluate the effects of shortwave diathermy therapy on pain, grip strength, and functionality in patients with hand osteoarthritis.

patients who apply to the physical medicine and rehabilitation outpatient clinic between january 2024 and february 2025 will be included in the study according to the inclusion and exclusion criteria specified below. demographic data of the patients such as age, gender, height, and weight will be recorded. in the initial evaluation, vas, hand dynamometer and pinchmeter measurements, duruöz hand index questionnaire and moberg addition test results of the patients will be noted. the g\*power 3.1 (faul, erdfelder, lang, and buchner, 2007) program was used to calculate the sample size. in the comparisons of different parameters between groups in reference studies, the effect size was calculated to be at the level of 0.9. this corresponds to a large level according to cohen's effect size classification. accepting a statistical significance coefficient of 0.05 with an effect size of 0.9, it was decided to include a minimum of 16 people in each group to obtain 80% power. a total of 36 patients (with a 10% drop-out margin) will be included in the study and will be randomly divided into two groups as treatment and control groups. randomization will be done by closed envelope method. the treatment group will be given 15 sessions: 20 minutes (27.12 mhz, continuous mode, 400w output) short wave diathermy treatment, hand osteoarthritis exercise program. the control group will be given 15 sessions: sham short wave diathermy and hand osteoarthritis exercise program. patients will complete 15 sessions, 1 session per day, 5 sessions per week. all evaluation parameters will be recorded before treatment, at the end of treatment and at the end of treatment at the 12th week. intra-group and inter-group differences will be examined statistically.

Eligibility criteria:
inclusion criteria: * to be between 35-75 years old * diagnosis of hand osteoarthritis according to the acr 1990 criteria exclusion criteria: * chronic inflammatory diseases (rheumatoid arthritis, seronegative spondyloarthropathy, gout, hemochramatosis, etc.) * malignancy * having uncontrolled systemic disease (cardiovascular, pulmonary, hematologic, hepatic, renal, endocrinologic) * synovitis, tenosynovitis, entrapment neuropathy, contracture, open wound in hand/wrist * history of hand fracture and/or operation * regular use of nonsteroidal anti-inflammatory drugs in the last three weeks * regular use of diaserin, chondroitin sulfate, glucosamine in the last three months * body mass index greater than 35

Keywords: hand osteoarthritis short wave diathermy shortwave diathermy
different protocols for repeated transarterial chemoembolization in the treatment of patients with hepatocellular carcinoma

Conditions: Liver Cancer

Summary: to evaluate local tumor control and survival rate after repeated transarterial chemoembolization(tace) using three different protocols in hepatocellular carcinoma (hcc) patients.


Eligibility criteria:
inclusion criteria: * patients with histologically confirmed hcc with unresectable disease without extrahepatic metastases; * hcc with no previous treatment; * age between 18 and 75 years; * life expectancy of at least 8 weeks; * main tumor size greater than 5 cm; * adequate hematologic function (platelet count: \>60 × 109 platelets/l; hemoglobin: \>90g/l; and prothrombin time: \<3 seconds above control); * adequate renal function (serum creatinine: ≤1.5 × upper limit of normal); * child-pugh classification a or b grade; * barcelona clinic liver cancer (bclc) stage b or c; * eastern co-operative group performance status of zero or one. exclusion criteria: * a hypovascular tumor (defined as a tumor with all its parts less contrast-enhanced than the nontumorous liver parenchyma on arterial phase computed tomography scans); * diffuse-type hcc; * evidence of hepatic decompensation including esophageal or gastric variceal bleeding or hepatic encephalopathy; * severe underlying cardiac or renal diseases; * color doppler ultrasonography showing portal vein tumor thrombosis with complete main portal vein obstruction without cavernous transformation; or obstructive jaundice.

Keywords: hepatocellular carcinoma transarterial chemoembolization gemcitabine
the efficacy of alcohol after betadine and combination of alcohol and betadine on inflammation vascular access

Conditions: Complication of Hemodialysis

Summary: the purpose of this study was to compare the efficacy of combination of alcohol and povidone iodine 10% and alcohol 70% after povidone iodine 10% on inflammation and infection related to vascular access area in hemodialysis patients.

these cases were identified from patient that lack of specific diseases; non-use of antibiotics or immunosuppressive drugs. that the participants will be selected using convenience sampling method and randomly divided into three groups: combination of alcohol and povidone iodine 10%, alcohol after and control groups. in the intervention in one group the vascular access site disinfected with alcohol(group1) and in group 2, alcohol and povidone iodine 10% was used to separate were disinfected. then the patient in a month of inflammation and infection of the vascular access will be monitor. exclusion criteria: inflammation or fistula failure during the study for any reason other than infection. sample size determination: through the pilot study. date: 02.10.2014 till 02.11.2014 outcome: washing with both solution affected on reduce the inflammation and infection of the patient. the efficacy of alcohol after betadine and combination of alcohol and betadine on inflammation and infection related to vascular access hemodialysis patients.

Eligibility criteria:
inclusion criteria: * absence of inflammatory vascular access site * three dialysis sessions per week exclusion criteria: * patient dies * patient withdrew from the partnership
comparison of the effect of testosterone administered for micropenis hypospadias surgery with bispectral index

Conditions: General Anesthesia; Testosterone; BIS

Summary: the aim of this observational study is to learn the effects of hormone therapy (testosterone) applied in micropenis hypospadias surgery on the depth of anesthesia under general anesthesia. the main question it aims to answer is: the effect of testosterone therapy on the depth of general anesthesia. based on these, to comment on the depth of anesthesia of patients who have just started using testosterone for sex change. to follow the depth of anesthesia of patients who have undergone hypospadias surgery with bis monitoring and to record respiratory parameters under general anesthesia.


Eligibility criteria:
inclusion criteria: * ages 1-16 * patients with asa i (normal healthy patients except for surgery) * patients who will undergo surgery for hypospadias repair exclusion criteria: * morbidly obese patients (body mass index \> 40kg/m2) * asa ii-iii-iv patients (other groups of patients with additional diseases) * volunteers who do not want to participate in the study
prospective study of an human endometrial receptivity test

Conditions: Infertile

Summary: evaluation of endometrial receptivity is a crucial step in in vitro fertilization/intracytoplasmic sperm injection (ivf/icsi) programs. using "omic technologies", such as transcriptomic and proteomic analyses, the investigators previously identified a specific molecular signature of human endometrial receptivity during the embryo implantation window. after validation of this signature in fertile women and in an ex vivo model (i.e., stromal and epithelial endometrium cells),the investigatorsdeveloped a diagnostic tool called win-test (window implantation test) to evaluate the expression level of a set of endometrial receptivity-specific genes during the implantation window by quantitative rt-pcr. based on their expression, each endometrial biopsy sample can be classified as receptive, partially receptive or non-receptive. then, after the identification of the right cycle day within the implantation window where endometrium is considered as receptive, a customized timing for embryo transfer with respect of the synchronization of the embryo-maternal dialogue must be performed. a prospective study to validate the relevance of the win-test, is a necessary step to gauge its effectiveness. in this objective, patients with multiple implantation failures will be recruited. embryo transfers were performed in double-arm: the intervention group had a customized timing of embryo transfer according to the win-test strategy and recommendation, the control group had their embryos transferred in a classical timing. pregnancy and live birth rates (lbr) were compared between groups.


Eligibility criteria:
inclusion criteria : * infertile patients associated with multiple implantation failures. * signatures consent and non-opposition letter. * patients with a standard infertility assessment. * patients with a monitored cycle (ultrasound, hormonal markers) during the mock frozen embryo transfer cycle to perform the win-test and during the embryo transfer cycle. * patients with complete treatment information during the mock frozen embryo transfer cycle to perform the win-test and during the embryo transfer cycle. * patients with accurate transfer day information. * patients for whom we have the outcome (pregnancy, live birth). exclusion criteria: more than 24 weeks of amenorrhea

Keywords: endometrial receptivity assessment for customized embryo transfer human reproduction art endometrial receptivity
development and validation of the glori-copd score

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the objective of this study is to evaluate the diagnostic accuracy of the glori-copd score in ambulatory care, to enable the screening of copd patients at risk of complications, requiring early management

chronic obstructive pulmonary disease (copd) is a chronic disease with a high prevalence in france, but which remains under-diagnosed due to the trivialization of symptoms and difficulty in accessing diagnostic investigations. it is associated with other co-morbidities, with an impact on the occurrence of complications and quality of life. early management of the most severe patients would allow better control of these risks of complications. our objective is to better identify patients with copd at risk of complications in general practice, taking into account the totality of the patient, to improve their management.

Eligibility criteria:
inclusion criteria: * age ≥ 35 yo * smoker or former smoker ≥ 10 pack years exclusion criteria: * patients who have already been diagnosed with copd by spirometry, * have a contraindication to spirometry, * have an estimated life expectancy of less than 5 years * are under protective measures
open-label extension study for subjects with h1 antihistamine refractory chronic spontaneous urticaria completing study ak006-001

Conditions: Chronic Spontaneous Urticaria

Summary: an open label extension (ole) study offered to subjects with chronic spontaneous urticaria that have completed the ak006-001 (nct06072157) part c referred to as the main study portion of the study. qualified subjects will receive up to four doses of the study drug (ak006) through an intravenous infusion every 4 weeks. there is a 16-week follow up period once all the scheduled infusions have been completed. subjects will be follow for evaluation of safety, tolerability, pk, immunogenicity, and clinical response.


Eligibility criteria:
key inclusion criteria: * enrolled in part c of study ak006-001 (nct06072157) and completed the randomized, double-blind, placebo-controlled treatment period and the day 99 visit. * acceptable demonstration of tolerance to study drug during the ak006-001 study as determined by the investigator. * acceptable demonstration of protocol compliance during the ak006-001 study as determined by the investigator. * female subject of childbearing potential and male subject with female partner of childbearing potential must agree to use a highly effective method of contraception with \<1% failure rate or abstain from sexual activity from screening until the end of the study, or for 16 weeks following the last dose of ak006, whichever is longer. key exclusion criteria: * pregnant, breastfeeding, or planning to become pregnant while participating in the study. * planned use of an approved or investigational therapy to treat csu other than a single 2nd- or later-generation h1-ah between 1× and 4× the licensed dose and frequency, during the study.
urine alkalinisation to prevent aki in covid-19

Conditions: Covid19

Summary: the aim is to explore the feasibility and safety of urine alkalinisation in critically ill patients with covid-19.

severe acute kidney injury appears to a major part of the sars-cov-2 syndrome. preventing early acute kidney injury may reduce severe aki as the disease progresses. urine alkalinisation to prevent binding of sars-cov-2 to renal tubular epithelial cells is a novel concept that could be used to design other therapies to reduce viral binding. showing feasibility with this safe and available strategy could be the first step toward other related efforts.

Eligibility criteria:
inclusion criteria: * confirmed covid-19 positive * admission to critical care unit * bladder catheter in situ * central line in place (including picc line) * age ≥18y * written informed consent to participate in the study exclusion criteria: * stage 3 aki (as defined by kdigo criteria) * chronic kidney disease stage 4 or 5 * contraindications to nahco3 therapy (e.g. risk of serious drug interaction, systemic metabolic alkalosis, congestive heart failure) * urine ph \> 7.0 * serum sodium \>150mmol/l * blood pressure \>180/100mghg * severe hypokalaemia (k\<3.0mmol/l) * inability to grant informed consent * severe hypocalcaemia (cai \<0.8 mmol/l) * pregnant or lactating and breast-feeding women * unwilling to use contraception * patient is on a medication that may interact with sodium bicarbonate
iron absorption and transfer to the fetus during pregnancy in normal weight and overweight/obese women and the effects on infants iron status

Conditions: Overweight; Obesity; Pregnancy

Summary: overweight and obesity causes low-grade systemic inflammation, which sharply increases risk for iron deficiency. studies in our laboratory have shown that this is mainly the result of reduced dietary iron absorption because of increased hepcidin concentrations. during pregnancy, women have a large increase in iron needs because of the expansion of maternal blood volume and fetal needs. iron deficiency anemia in infancy can impair cognitive development. whether maternal adiposity impairs absorption and transfer of iron to the fetus, and thereby increases risk of iron deficiency in the mother and the infant is unclear.

in obese subjects, hepcidin concentrations are increased and iron absorption is believed to be reduced, leading to iron deficiency over time. how all this will influence iron supply of the fetus in obese pregnancy has not been well investigated to date. even if maternal and fetal iron uptakes are regulated separately, it is unclear to what extent maternal subclinical inflammation might influence this process. a small study by dao et al. indicated that maternal-fetal iron transfer was impaired in obese pregnant women, possibly due to hepcidin up-regulation. in this study, both maternal bmi as well as hepcidin were negatively correlated with cord blood iron status. maternal hepcidin and c-reactive protein were significantly higher and cord blood iron was significantly lower in the obese compared to the normal weight. hepcidin was shown to have an effect on iron transfer across the placenta in the study by young et al.: the transfer was increased in women with undetectable hepcidin at delivery compared to those with higher levels. as of now, clear associations between maternal bmi or maternal hepcidin concentration and fetal iron status were not shown.

Eligibility criteria:
inclusion criteria: * pregnant women with either normal pre-pregnancy bmi (bmi 18.5 - 24.9kg/kg2) or with overweight or obesity (bmi \> 27.5kg/m2) before pregnancy (assessed based on data reported by the women at their first visit at the hospital) * 18 to 45 years old * singleton pregnancy * week of pregnancy 14±3 exclusion criteria: * underlying malabsorption disease * chronic illness, which influences iron absorption * inflammatory status other than obesity * medical problems known to affect iron homeostasis * smoking during pregnancy * no regular use of medication, which influences iron absorption

Keywords: iron bioavailability hepcidin iron absorption
safety and pharmacokinetics study of xoma 052 in subjects with active, stable, moderate to severe rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: study x052070 will evaluate the safety and pharmacokinetics (pk) of xoma 052 administered to patients with active, stable, moderate to severe rheumatoid arthritis (ra). it is hypothesized that administration of xoma 052 is likely to improve inflammatory control in subjects with ra.


Eligibility criteria:
inclusion criteria: * american college of rheumatology (acr) diagnostic criteria for ra * moderate to severe disease, defined as follows - at least six tender and six swollen joints (28 joint count) and esr \> 28 mm/hr or crp \> 1.0 mg/dl * current duration of ra at screening ≥ 6 months and ≤ 20 years * ra and other medical conditions must be stable. * age ≥ 18 and ≤ 75 at screening * weight ≥ 80 lbs (36.3 kg) and ≤ 275 lbs (125.0 kg) * for females with child-bearing potential, a negative serum pregnancy test exclusion criteria: * major surgery within 28 days prior to day 0 * joint replacement surgery within 60 days prior to day 0 or joint replacement surgery planned within 9 months following day 0 * known hiv antibody, or hepatitis b surface antigen * history of malignancy within 5 years prior to screening other than carcinoma in situ of the cervix, or adequately treated, non-metastatic squamous or basal cell carcinoma of the skin * immunodeficiency * history or symptoms of a demyelinating disease * history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies. respiratory distress (dyspnea, oxygen desaturation with po2 \< 90% or onset of acute respiratory distress syndrome), flank or back pain, and/or hypotension may be signs of anaphylaxis. * history of tuberculosis, positive ppd test, active atopic disease requiring medication, or asthma. a subject who has had a positive ppd test but has completed a course of treatment for tuberculosis, had a documented vaccination against tuberculosis, or had a negative quantiferon -tb test result is eligible. * chronic obstructive pulmonary disease (copd), asthma, or other pulmonary disease requiring more therapy than using one inhaler 4× daily * significant systemic involvement secondary to ra (e.g. vasculitis, pulmonary fibrosis) * liver disease (e.g., hepatitis, cirrhosis) or abnormal hepatic function. if the diagnosis of liver disease was based on positive hep c serology due to prior vaccination, the subject is eligible. * pregnant or planning to become pregnant during the course of the study, or breast-feeding

Keywords: rheumatoid arthritis
morbidly adherent placenta, diagnosis and proper management

Conditions: Morbidly Adherent Placenta

Summary: the main idea of this study is to establish the diagnostic criteria for cases of morbidly adherent placenta (map) using different ultrasonographic modalities and compare this with intra-operative findings and postoperative histopathological assessment

this study is a clinical trial that will include all patients fulfilling the eligibility criteria and presented to the emergency unit of the department of obstetrics and gynecology in sohag university hospital (egyptian tertiary referral hospital) between february 2022 and february 2023. the attending physician will explain the nature of the study and all patients will be asked to sign an informed consent. a senior physician will evaluate the patient to confirm the diagnosis of placenta previa and degree of invasion in query accreta patients by using transabdominal and transvaginal us (voluson,p8). 2d gray scale ultrasound, color and power doppler ultrasound will be performed firstly followed by 3d ultrasound. all data will be saved in closed excel sheet and patients will be operated by a different surgical team, intraoperative staging of degree of placental invasion will be done according to clinical grading system by collins et al., 2015 \[5\] in addition to histopathological evaluation when available, such as in cases of hysterectomy and cases with anterior placenta who were treated by excision of part of anterior uterine wall suitable for histopathological evaluation.

Eligibility criteria:
inclusion criteria: * o all pregnancies complicated with any degree of placenta previa anterior, posterior or centralis undergoing pre-labor cs at gestational age (36+0 to 40+0), patients will be divided into subgroups according to number of previous cs, presence or absence of antepartum hemorrhage and qualifications of operative theatre in previous deliveries (public or private sector). exclusion criteria: * women with history of medical co-morbidities such as chronic hypertension, diabetes mellitus, renal diseases, autoimmune diseases, history of organ transplantation and immunosuppressive therapy, hematological diseases, history of thrombotic events, cardiopulmonary diseases, liver diseases acute and chronic inflammatory diseases. * pregnancy induced medical disorders like: gestational hypertension, preeclampsia, gestational diabetes, gestational thrombocytopenia and proteinuria. * fetal anomalies. * emergency cs if the patient is in labor.

Keywords: ultrasonography intraoperative staging histopathological assessment